Skip to main content

Advertisement

Log in

Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Lipid accumulation product (LAP) and visceral adiposity index (VAI) are surrogates for visceral adiposity dysfunction. Our aim was to evaluate potential association of these two indices with the incidence of renal function decline.

Methods

We included 6693 non-diabetic adults age ≥ 18 years, with estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73 m2, from the Tehran Lipid and Glucose Study 2002–2005 survey. Natural logarithmic transformation (Ln) was applied for LAP and VAI measures. The incidence of renal function decline, defined as eGFR < 60 ml/min/1.73 m2, was evaluated for each gender, across tertiles of Ln LAP, Ln VAI, body mass index (BMI), waist circumference (WC), waist to height ratio (WHtR) and waist to hip ratio (WHR), using Cox-proportional hazard models.

Results

Over a median 8.6 years of follow-up, 1670 new cases of renal function decline were identified (incidence rate 3.2%). After multivariable adjustment, the hazard ratios (HRs) with 95% CI across second and third tertiles of Ln LAP were 1.14 (0.86–1.50) and 1.33 (1.00–1.78) in men (P trend = 0.132); and 1.16 (0.90–1.50) and 1.24 (0.96–1.61) in women (P trend = 0.263), respectively. Multivariable adjusted HRs across second and third tertiles of Ln VAI were 1.40 (1.08–1.83) and 1.35 (1.02–1.78) in men (P trend = 0.031); and 0.93 (0.75–1.15) and 1.15 (0.93–1.41) in women (P trend = 0.072), respectively. HRs across tertiles of BMI, WC, WHtR and WHR were not significant for renal function decline among both genders in any adjustment models.

Conclusion

Among the adiposity indices assessed in this study, VAI seems to be an independent predictor of renal function decline only in males.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.

    Article  Google Scholar 

  2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034–47.

    Article  Google Scholar 

  3. Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224–35.

    Article  Google Scholar 

  4. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301.

    Article  Google Scholar 

  5. Tchernof A, Després J-P. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.

    Article  CAS  Google Scholar 

  6. Kim SR, Yoo JH, Song HC, Lee SS, Yoo SJ, Kim Y-D, et al. Relationship of visceral and subcutaneous adiposity with renal function in people with type 2 diabetes mellitus. Nephrol Dial Transplant. 2010;26(11):3550–5.

    Article  Google Scholar 

  7. Alvehus M, Burén J, Sjöström M, Goedecke J, Olsson T. The human visceral fat depot has a unique inflammatory profile. Obesity. 2010;18(5):879–83.

    Article  CAS  Google Scholar 

  8. Shuster A, Patlas M, Pinthus J, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1–10.

    Article  CAS  Google Scholar 

  9. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2.

    Article  Google Scholar 

  10. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disorders. 2005;5(1):26.

    Article  Google Scholar 

  11. Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS Database Study. Obesity. 2010;18(9):1836–44.

    Article  CAS  Google Scholar 

  12. Bozorgmanesh M, Hadaegh F, Azizi F. Diabetes prediction, lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9(1):45.

    Article  Google Scholar 

  13. Kouli G-M, Panagiotakos DB, Kyrou I, Georgousopoulou EN, Chrysohoou C, Tsigos C, et al. Visceral adiposity index and 10-year cardiovascular disease incidence: the ATTICA study. Nutr Metab Cardiovasc Dis. 2017;27(10):881–9.

    Article  Google Scholar 

  14. Chen Y-C, Lai S-H, Tsai Y-W, Chang S-S. Visceral adiposity index as a predictor of chronic kidney disease in a relatively healthy population in Taiwan. J Renal Nutr. 2018;28(2):91–100.

    Article  Google Scholar 

  15. Dai D, Chang Y, Chen Y, Chen S, Yu S, Guo X, et al. Visceral adiposity index and lipid accumulation product index: two alternate body indices to identify chronic kidney disease among the rural population in Northeast China. Int J Environ Res Pub Health. 2016;13(12):1231.

    Article  Google Scholar 

  16. Zhang K, Li Q, Chen Y, Wang N, Lu Y. Visceral adiposity and renal function: an observational study from SPECT-China. Lipids Health Dis. 2017;16(1):205.

    Article  Google Scholar 

  17. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10(1):5.

    Article  Google Scholar 

  18. Association AD. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97.

    Article  Google Scholar 

  19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  Google Scholar 

  20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.

    Article  CAS  Google Scholar 

  21. Expert Panel on Detection E. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486.

    Article  Google Scholar 

  22. Committee IR. Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ)-short and long forms. http://www.ipaq.ki.se/scoring.pdf. 2005.

  23. Onat A, Avcı GŞ, Barlan M, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes. 2004;28(8):1018.

    Article  CAS  Google Scholar 

  24. Oh H, Quan SA, Jeong J-Y, Jang S-N, Lee JE, Kim D-H. Waist circumference, not body mass index, is associated with renal function decline in korean population: hallym aging study. PLoS One. 2013;8(3):e59071.

    Article  CAS  Google Scholar 

  25. Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis. 2008;52(1):29–38.

    Article  Google Scholar 

  26. Odagiri K, Mizuta I, Yamamoto M, Miyazaki Y, Watanabe H, Uehara A. Waist to height ratio is an independent predictor for the incidence of chronic kidney disease. PLoS One. 2014;9(2):e88873.

    Article  Google Scholar 

  27. Lemieux I, Pascot A, Couillard C, Lamarche BT, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2):179–84.

    Article  CAS  Google Scholar 

  28. Ramezankhani A, Azizi F, Ghanbarian A, Parizadeh D, Hadaegh F. The hypertriglyceridemic waist and waist-to-height ratio phenotypes and chronic kidney disease: cross-sectional and prospective investigations. Obes Res Clin Pract. 2017;11(5):585–96.

    Article  Google Scholar 

  29. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28(10):2436–40.

    Article  Google Scholar 

  30. Jadhakhan F, Marshall T, Ryan R, Gill P. Risk of chronic kidney disease in young adults with impaired glucose tolerance/impaired fasting glucose: a retrospective cohort study using electronic primary care records. BMC Nephrol. 2018;19(1):42.

    Article  Google Scholar 

  31. Pscheidt C, Nagel G, Zitt E, Kramar R, Concin H, Lhotta K. Sex-and time-dependent patterns in risk factors of end-stage renal disease: a large Austrian cohort with up to 20 years of follow-up. PLoS One. 2015;10(8):e0135052.

    Article  Google Scholar 

  32. Wang X, Fan F, Jia J, Xu X, Qin X, Zheng B, et al. Association of different glucose traits with kidney function decline risk in a Chinese community-based population without chronic kidney disease. Ther Clin Risk Manag. 2018;14:1725.

    Article  CAS  Google Scholar 

  33. Neamat-Allah J, Wald D, Hüsing A, Teucher B, Wendt A, Delorme S, et al. Validation of anthropometric indices of adiposity against whole-body magnetic resonance imaging—a study within the German European Prospective Investigation into Cancer and Nutrition (EPIC) Cohorts. PLoS One. 2014;9(3):e91586.

    Article  Google Scholar 

  34. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens. 2006;15(2):173–8.

    Article  Google Scholar 

  35. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58(5):784–90. https://doi.org/10.1161/HYPERTENSIONAHA.111.175315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013;305(12):F1629–36.

    Article  CAS  Google Scholar 

  37. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837–46.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Study conception and design by FH. Literature search, interpretation and manuscript preparation by PM. Data collection and analysis by PM, MB and MM. Manuscript review, critical appraisal and specialist advices by MV, FA and FH. All authors have revised and approved the submitted manuscript.

Corresponding author

Correspondence to Farhad Hosseinpanah.

Ethics declarations

Conflict of interest

All the authors have declared no competing interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mousapour, P., Barzin, M., Valizadeh, M. et al. Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up. Clin Exp Nephrol 24, 225–234 (2020). https://doi.org/10.1007/s10157-019-01813-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-019-01813-7

Keywords

Navigation